Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caliper Life Sciences Forms Alliance with Horizon Discovery

Published: Thursday, April 10, 2008
Last Updated: Thursday, April 10, 2008
Bookmark and Share
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.

Caliper Life Sciences, Inc. has announced a partnership with Horizon Discovery Ltd. (Cambridge, UK) that expands Caliper Discovery Alliances and Services' (CDAS) oncology cell line and screening capabilities for testing single drugs and combination therapies.

Through this alliance, CDAS now offers genetically-defined, and isogenic human cancer cell lines that allow researchers to better identify and characterize personalized drugs targeted at a specific subset of patients.

Isogenic cell-line pairs, where one cell line contains a genetic alteration or mutation of interest and the other contains the normal gene, represent cell-based models that accurately portray specific human diseases in the context of their matched normal genetic backgrounds.

The inclusion of isogenic cell-line pairs in the discovery process enables scientists to better understand the mechanism of action of lead compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new therapeutic indications, assess the efficacy of drug combinations, and identify potential side effects earlier in the discovery process.

"The alliance with Horizon Discovery adds significant value to existing CDAS offerings and illustrates Caliper's commitment to providing accurate in vitro and in vivo models for oncology research," said David Manyak, Executive Vice President of Drug Discovery Services, Caliper Life Sciences.

"The addition of Horizon's isogenic cell lines to our existing oncology cell proliferation panel, and the ability to correlate results from these isogenic cell lines to efficacy in specific patient populations, further solidifies Caliper's in vitro-in vivo-human (IIH) bridge. Access to these tools will enable researchers to enhance the success rate and reduce the cost of discovering targeted monotherapy or combination therapies that better treat disease with fewer adverse events," he added.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!